Hodgkin lymphoma: A curable disease: What comes next?

European Journal of Haematology, Supplement

Volumn 75, Issue 66, 2005, Pages 6-13

  Diehl, Volker ^a,b   Klimm, Beate ^a   Re, Daniel ^a  

^a German Hodgkin Study Group   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BORTEZOMIB; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IBRITUMOMAB TIUXETAN; MDX 060; MONOCLONAL ANTIBODY; PREDNISONE; PROCARBAZINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RITUXIMAB; SGN 30; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; DRUG EFFICACY; HODGKIN DISEASE; HUMAN; PATIENT SELECTION; PHARMACOGENOMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; CLINICAL TRIAL; EDITORIAL; MORTALITY; RADIOTHERAPY; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HODGKIN DISEASE; HUMANS; RADIOTHERAPY; SURVIVAL ANALYSIS;

EID: 84900402948     PISSN: 09024506     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. DE VITA VT Jr, HUBBARD SM. Hodgkin's disease. N Engl J Med 1993;328:560-565.
2. BONADONNA G, ZUCALI R, MONFARDINI S Jr, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboximide versus MOPP. Cancer 1975;36:252-259.
3. HORNING SJ, HOPPE RT, BRESLIN S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002;20:630-637.
4. DIEHL V, FRANKLIN J, PFREUNDSCHUH M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395.
5. RADFORD JA, ROHATINER AZ, RYDER WD, et al. ChlVPP/ EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 2002;20:2988-2994.
6. DIEHL V, BRILLANT C, ENGERT A, et al. Reduction of combined modality treatment intensity in early stage Hodgkin's lymhoma: interim analysis of the HD10 trial of the GHSG. Eur J Hematol 2004;73(Suppl. 65):37.E03.
7. HORWICH A, SPECHT L, ASHLEY S. Survival analysis of patients with clinical stages 1 or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 1997;33:848-853.
8. DIEHL V, BRILLANT C, ENGERT A, et al. Intensification of chemotherapy and concomitant reduction of radiotherapy dose in intermediate stage Hodgkin's lymphoma: results of the fourth interim analysis of the HD 11 trial of the GHSG. Eur J Hematol 2004;73(Suppl. 65):37.E02.
9. CANELLOS GP, NIEDZWIECKI D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002;346:1417-1418.
10. DIEHL V, BRILLANT C, FRANKLIN J, et al. Beacopp Chemotherapy for Advanced Hodgkin's Disease: results of further analyses of the HD9- and HD12-trials of the German Hodgkin Study Group (GHSG). Blood 2004;104:307a.
11. SIEBER M, BREDENFELD H, JOSTING A, et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:1734-1739.
12. KUPPERS R, KLEIN U, SCHWERING I, et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest 2003;111:529-537.
13. EKSTRAND BC, LUCAS JB, HORWITZ SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003;101:4285-4289.
14. REHWALD U, SCHULZ H, REISER M, et al. German Hodgkin Lymphoma Study Group (GHSG). Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003;101:420-424.
15. BORCHMANN P, TREML JF, HANSEN H, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 2003;102:3737-3742.
16. LEONARD JP, ROSENBLATT JD, BARTLETT NL, et al. Phase II study of SGN-30 (Anti-CD30 Monoclonal Antibody) in patients with refractory or recurrent Hodgkin's disease. Blood 2004;104:721a (abstract 2635).
17. POGGE E, BOELL B, TAWADROS S, et al. The human anti-CD30 antibody 5F11 activates NF-kB and sensitizes lymphoma cells to bortezomib induced apoptosis. Blood 2004;104:900a (abstract 3295).
18. PEDERSEN IM, KITADA S, SCHIMMER A, et al. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood 2002;100:2965-2972.